Prognostic factors and therapeutic effects of different treatment modalities for colorectal cancer liver metastases

Table 1 Comparison of clinicopathological data of the four groups of patients

	Drug	Ablation	Intervention	Surgical resection	Statistical value	P value
Gender					χ2 = 2.459	0.483
Male	8	19	10	24
Female	5	4	5	12
Age (yr)	62.77 ± 8.55	60.39 ± 9.33	63.13 ± 10.57	57.50 ± 12.52	F = 1.337	0.268
Primary tumor size (cm)	5.08 ± 2.17	4.35 ± 1.40	5.37 ± 2.72	5.10 ± 2.06	F = 0.940	0.425
Primary tumor site					χ2 = 11.729	0.068
Right colon	6	6	3	7
Left colon	5	4	3	16
Rectum	2	13	9	13
Pathological type					χ2 = 3.032	0.387
Non-MUC	11	20	11	33
MUC	2	3	4	3
Differentiation					χ2 = 7.807	0.253
High	4	4	1	10
Moderate	7	13	8	22
Low	2	6	6	4
CEA (ng/mL)					χ2 = 2.950	0.339
≤ 15	11	13	10	24
> 15	2	10	5	12
CA19-9 (U/mL)					χ2 = 0.576	0.902
≤ 37	10	15	10	25
> 37	3	8	5	11
LMN					χ2 = 4.346	0.226
No	6	14	7	12
Yes	7	9	8	24
CLM distribution					χ2 = 17.169	0.009
Right lobe	4	15	4	14
Left lobe	5	0	1	5
Both lobes	4	8	10	17
CLM number					χ2 = 5.051	0.168
≤ 4	8	16	5	21
> 4	5	7	10	15
Proximity to great vessels					χ2 = 23.693	0.000
No	12	21	5	31
Yes	1	2	10	5
Maximum CLM diameter (cm)	4.96 ± 2.81	4.72 ± 1.74	5.03 ± 1.39	2.93 ± 1.11	F = 9.627	0.000
Total chemotherapy time					χ2 = 5.729	0.126
< 6 mo	13	18	14	27
≥ 6 mo	0	5	1	9

MUC: Mucinous colorectal adenocarcinomas; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; LMN: Lymph node metastases; CLM: Colorectal liver metastases.